CD274 and neoplasm: PD-L1 expression is typically assessed through immunohistochemistry on cancerous tumor tissue biopsies, either solely on the tumor cells or on both the tumor cells and the adjacent infiltrated immune cells, providing a quantifiable measure of PD-L1 protein levels as a tumor proportional score (TPS) or combined positive score (CPS), respectively [93,94].